Validity, prognostic value and optimal cutoff of respiratory muscle strength in patients with chronic heart failure changes with beta-blocker treatment

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue 4, 2009, Pages 424-429

  Frankenstein, Lutz ^a   Nelles, Manfred ^a   Meyer, F Joachim ^a   Sigg, Caroline ^a   Schellberg, Dieter ^a   Remppis, B Andrew ^a   Katus, Hugo A ^a   Zugck, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adrenergic beta antagonists; Beta blocker; Congestive heart failure; Maximal inspiratory mouth occlusion pressure; PImax; Prognosis; Respiratory muscle function tests; Risk stratification

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

ADULT; ARTICLE; BREATHING MUSCLE; CLINICAL EVALUATION; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE STRENGTH; OBSERVATIONAL METHOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESPIRATORY FUNCTION; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; VALIDITY;

EID: 66749143186     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3283030a7e     Document Type: Article

References (32)

1. Witt C, Borges AC, Haake H, Reindl I, Kleber FX, Baumann G. Respiratory muscle weakness and normal ventilatory drive in dilative cardiomyopathy. Eur Heart J 1997; 18:1322-1328.
2. Hammond MD, Bauer KA, Sharp JT, Rocha RD. Respiratory muscle function in congestive heart failure. Chest 1990; 98:1091-1094.
3. Mancini DM, Henson D, LaManca J, Levine S. Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 1992; 86:909-918.
4. Meyer FJ, Zugck C, Haass M, Otterspoor L, Strasser RH, Kubler W, et al. Inefficient ventilation and reduced respiratory muscle capacity in congestive heart failure. Basic Res Cardiol 2000; 95:333-342.
5. Dall'Ago P, Chiappa GR, Guths H, Stein R, Ribeiro JP. Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J Am Coll Cardiol 2006; 47:757-763.
6. Laoutaris I, Dritsas A, Brown MD, Manginas A, Alivizatos PA, Cokkinos DV. Inspiratory muscle training using an incremental endurance test alleviates dyspnea and improves functional status in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004; 11:489-496.
7. McConnell TR, Mandak JS, Sykes JS, Fesniak H, Dasgupta H. Exercise training for heart failure patients improves respiratory muscle endurance, exercise tolerance, breathlessness, and quality of life. J Cardiopulm Rehabil 2003; 23:10-16.
8. Mancini DM, Henson D, La Manca J, Donchez L, Levine S. Benefit of selective respiratory muscle training on exercise capacity in patients with chronic congestive heart failure. Circulation 1995; 91:320-329.
9. Weiner P, Waizman J, Magadle R, Berar-Yanay N, Pelled B. The effect of specific inspiratory muscle training on the sensation of dyspnea and exercise tolerance in patients with congestive heart failure. Clin Cardiol 1999; 22 :727-732.
10. Larsen AI, Gjesdal K, Hall C, Aukrust P, Aarsland T, Dickstein K. Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. Eur J Cardiovasc Prev Rehabil 2004; 11:162-167.
11. Maria Sarullo F, Gristina T, Brusca I, Milia S, Raimondi R, Sajeva M, et al. Effect of physical training on exercise capacity, gas exchange and N-terminal pro-brain natriuretic peptide levels in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2006; 13:812-817.
12. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 2001; 103:2153-2158.
13. Mucciardi N, Muspratt J, Miller MJ. Propranolol and inspiratory muscle performance in normal subjects. J Clin Pharmacol 1988; 28:625-633.
14. Jindal MN, Shah UH, Patel VK, Kelkar VV. A study of some beta-adrenoceptor blocking agents on skeletal muscle. Arzneimittelforschung 1975; 25:52-55.
15. Wang YT, Poh SC. Lung function and respiratory muscle strength after propranolol in thyrotoxicosis. Aust N Z J Med 1986; 16:496-500.
16. Van der Heijden HF, Heunks LM, Folgering H, Van Herwaarden CL, Dekhuijzen PN. beta2-adrenoceptor agonists reduce the decline of rat diaphragm twitch force during severe hypoxia. Am J Physiol 1999; 276:L474-L480.
17. Witte KK, Clark AL. Beta-blockers and inspiratory pulmonary function in chronic heart failure. J Card Fail 2005; 11:112-116.
18. Pohwani AL, Murali S, Mathier MM. Impact of beta-blocker therapy on functional capacity criteria for heart transplant listing. J Heart Lung Transplant 2003; 22:78-86.
19. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002; 39:1615-1622.
20. Hulsmann M, Sturm B, Pacher R, Berger R, Bojic A, Frey B, et al. Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction. J Heart Lung Transplant 2001; 20:1174-1180.
21. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al.; Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
22. Frankenstein L, Remppis A, Graham J, Schellberg D, Sigg C, Nelles M, et al. Gender and age related predictive value of walk test in heart failure: do anthropometrics matter in clinical practice? Int J Cardiol 2007; [Epub ahead of print].
23. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107-115.
24. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166:518-624.
25. Harik-Khan RI, Wise RA, Fozard JL. Determinants of maximal inspiratory pressure. The Baltimore Longitudinal Study of Aging. Am J Respir Crit Care Med 1998; 158 (5 Pt 1):1459-1464.
26. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35.
27. Van der Palen J, Rea TD, Manolio TA, Lumley T, Newman AB, Tracy RP, et al. Respiratory muscle strength and the risk of incident cardiovascular events. Thorax 2004; 59:1063-1067.
28. Nishimura Y, Maeda H, Tanaka K, Nakamura H, Hashimoto Y, Yokoyama M. Respiratory muscle strength and hemodynamics in chronic heart failure. Chest 1994; 105:355-359.
29. Walsh JT, Andrews R, Johnson P, Phillips L, Cowley AJ, Kinnear WJ. Inspiratory muscle endurance in patients with chronic heart failure. Heart 1996; 76:332-336.
30. Opasich C, Ambrosino N, Felicetti G, Aquilani R, Pasini E, Bergitto D, et al. Heart failure-related myopathy. Clinical and pathophysiological insights. Eur Heart J 1999; 20:1191-1200.
31. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, et al. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail 2004; 10:15-20.
32. Frankenstein L, Meyer FJ, Sigg C, Nelles M, Schellberg D, Remppis A, et al. Is serial determination of inspiratory muscle strength a useful prognostic marker in chronic heart failure? Eur J Cardiovasc Prev Rehabil 2008; 15 :156-161.